Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 13, Issue 599, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.abg3071
Keywords
-
Categories
Funding
- Gilead Sciences
- National Institutes of Health (NIH) National Cancer Institute [P30 CA0933730]
- NIH National Center for Research Resources [C06-RR12088, S10-RR12964, S10-RR026825, S10OD018223-01A1]
- James B. Pendleton Charitable Trust
Ask authors/readers for more resources
TLR7 agonist vesatolimod, when combined with ART, showed potential to delay viral rebound in HIV-1-infected controllers by reducing intact proviral DNA levels at the end of treatment. Further larger clinical studies are needed to evaluate the efficacy of vesatolimod-based combination therapies for long-term control of HIV infection.
Toll-like receptor 7 (TLR7) agonists, in combination with other therapies, can induce sustained control of simian-human immunodeficiency virus (SHIV) or simian immunodeficiency virus (SIV) in nonhuman primates. Here, we report the results of a randomized, double-blind, placebo-controlled phase 1b clinical trial of an oral TLR7 agonist, vesatolimod, in HIV-1-infected controllers on antiretroviral therapy (ART). We randomized participants 2:1 to receive vesatolimod (n = 17) or placebo (n = 8) once every other week for a total of 10 doses while continuing on ART. ART was then interrupted, and the time to viral rebound was analyzed using the Kaplan-Meier method. Vesatolimod was associated with induction of immune cell activation, decreases in intact proviral DNA during ART, and a modest increase in time to rebound after ART was interrupted. The delayed viral rebound was predicted by the lower intact proviral DNA at the end of vesatolimod treatment (13 days after the final dose). Inferred pathway analysis suggested increased dendritic cell and natural killer cell cross-talk and an increase in cytotoxicity potential after vesatolimod dosing. Larger clinical studies will be necessary to assess the efficacy of vesatolimod-based combination therapies aimed at long-term control of HIV infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available